Trial reportDiagnostic pathology2019
Serum expression of selected miRNAs in patients with laryngeal squamous cell carcinoma (LSCC).
Trial report in Diagnostic pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Circulating miR-99a-5p and miR-1246 as Diagnostic and Stage-Associated Biomarkers in Laryngeal Squamous Cell Carcinoma.Biomedicines · 2026Article
- CircHMGA2 facilitates proliferation and invasion of laryngeal squamous cell carcinoma cells and M2 macrophage polarizationCentral-European journal of immunology · 2026Article
- Co-expression of miRNA players in advanced laryngeal carcinoma - Insights into the roles of miR-93-5p, miR-145-5p, and miR-210-3p.Biomolecules & biomedicine · 2025Article
- A Systematic Review of Circulating miRNAs Validated by Multiple Independent Studies in Laryngeal Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Identifying Biomarkers and Therapeutic Targets by Multiomic Analysis for HNSCC: Precision Medicine and Healthcare Management.ACS omega · 2024Article
- Biomarker Discovery in Rare Malignancies: Development of a miRNA Signature for RDEB-cSCC.Cancers · 2023Article
- hsa‑miR‑216a‑3p regulates cell proliferation in oral cancer via the Wnt3a/β‑catenin pathway.Molecular medicine reports · 2023Article
- Article
- Diagnostic and Prognostic Value of microRNAs in Patients with Laryngeal Cancer: A Systematic Review.Non-coding RNA · 2023Review
- miR-223: a key regulator of pulmonary inflammation.Frontiers in medicine · 2023Review
- miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023Review
- Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.International journal of molecular sciences · 2022Review
- Multiple microRNA signature panel as promising potential for diagnosis and prognosis of head and neck cancer.Molecular biology reports · 2022Review
- Clinical applications of liquid biopsy in HPV-negative and HPV-positive head and neck squamous cell carcinoma: advances and challenges.Exploration of targeted anti-tumor therapy · 2022Review
- A New Online Dynamic Nomogram: Construction and Validation of an Assistant Decision-Making Model for Laryngeal Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- The Role of Cell Organelles in Rheumatoid Arthritis with Focus on Exosomes.Biological procedures online · 2021Review
- Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.International journal of molecular sciences · 2020Review
- Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe aim of the present study was to identify specific serum miRNAs (preoperative serum samples compared to healthy controls) as potential diagnostic markers for detection in laryngeal squamous cell carcinoma (LSCC). Serum samples obtained from 66 patients with LSCC were compared with 100 healthy control subjects. Additionally, miRNA levels were evaluated to identify possible correlations with clinicopathological features.
methodsThe expression of 377 miRNAs (screening set) was evaluated by microarray screening. The most differentially expressed miRNAs were validated by high-throughput real-time quantitative polymerase chain reaction (RT-qPCR) in the group of LSCC patients and healthy controls. Receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s).
resultsAccording to the array analysis, eleven miRNAs revealed an altered expression profile. The levels of serum expression of miR-31, miR-141, miR-149a, miR-182, LET-7a, miR-4853p, miR-122 and miR-33 were up-regulated, and those of miR-145, miR-223 and miR-133a down-regulated, in the LSCC group compared to healthy controls. ROC curve analyses revealed an AUC (area under the ROC curve) of 1.00 (95%Cl: 0.999-1.00; P < 0.001) for miR-31 and LET-7a, 1.00 (95%Cl: 1.00-1.00; P < 0.001) for miR-33 respectively, indicating that these three miRNAs had an additive effect regarding diagnostic value. No statistically significant differences were found between the serum levels of these eleven miRNAs and the tested clinicopathological features.
conclusionOur findings outline a distinct miRNA expression profile in laryngeal cancer (LC) cases which can be used to diagnose LSCC patients with high sensitivity and specificity. Particular miRNA signatures (miR-31, LET-7a and miR-33) may be considered as novel, non-invasive biomarkers for LC diagnosis.
trial registrationRegistration number: RNN/203/13/KE. Date of registration 18.06.2013r.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.